Trial Profile

A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Dotinurad Compared With Allopurinol in Adult Participants With Hyperuricemia Associated With Gout

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 02 Mar 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

02 Feb 2026 According to a Crystalys Therapeutics media release, company announced that the first patients have been dosed at clinical sites in Europe
30 Sep 2025 According to a Crystalys Therapeutics media release, the $205 million Series A financing launched by the company will support the advancement of global Phase 3 clinical studies evaluating dotinurad, for the treatment of gout.
28 Aug 2025 Planned End Date changed from 1 Sep 2027 to 29 Nov 2027.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com